Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients
Acarbose is an α-glucosidase inhibitor that is commonly used to control postprandial blood glucose. It functions as a competitive and reversible inhibitor of small intestinal brush border glucosidase, blocks the degradation of starch and sucrose, and delays the absorption of glucose and fructose in...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085335/ |
| id |
pubmed-4085335 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-40853352014-07-24 Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients He, Ke Shi, Jun-Cheng Mao, Xiao-Ming Review Acarbose is an α-glucosidase inhibitor that is commonly used to control postprandial blood glucose. It functions as a competitive and reversible inhibitor of small intestinal brush border glucosidase, blocks the degradation of starch and sucrose, and delays the absorption of glucose and fructose in the alimentary tract. The starch content of a diet might alter the hypoglycemic effects of acarbose because of its mechanism of action. Chinese individuals consume a typical Eastern diet, which is characterized by a high intake of whole grains, legumes, vegetables, fruits, and fish. These dietary habits allow acarbose to be used extensively in the People’s Republic of China. Several Chinese-based studies have demonstrated that the use of acarbose as a monotherapy had similar effects on other anti-diabetes agents in decreasing glycosylated hemoglobin (HbA1c) and blood glucose levels, and acarbose in combination with other anti-diabetic drugs could further reduce blood glucose and decrease the mean amplitude of glycemic excursions. Importantly, acarbose is safe and well tolerated, with a low incidence of adverse effects. This article provides a comprehensive review of the safety and efficacy of acarbose for the treatment of diabetes in Chinese patients. Dove Medical Press 2014-06-30 /pmc/articles/PMC4085335/ /pubmed/25061309 http://dx.doi.org/10.2147/TCRM.S50362 Text en © 2014 He et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
He, Ke Shi, Jun-Cheng Mao, Xiao-Ming |
| spellingShingle |
He, Ke Shi, Jun-Cheng Mao, Xiao-Ming Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| author_facet |
He, Ke Shi, Jun-Cheng Mao, Xiao-Ming |
| author_sort |
He, Ke |
| title |
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| title_short |
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| title_full |
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| title_fullStr |
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| title_full_unstemmed |
Safety and efficacy of acarbose in the treatment of diabetes in Chinese patients |
| title_sort |
safety and efficacy of acarbose in the treatment of diabetes in chinese patients |
| description |
Acarbose is an α-glucosidase inhibitor that is commonly used to control postprandial blood glucose. It functions as a competitive and reversible inhibitor of small intestinal brush border glucosidase, blocks the degradation of starch and sucrose, and delays the absorption of glucose and fructose in the alimentary tract. The starch content of a diet might alter the hypoglycemic effects of acarbose because of its mechanism of action. Chinese individuals consume a typical Eastern diet, which is characterized by a high intake of whole grains, legumes, vegetables, fruits, and fish. These dietary habits allow acarbose to be used extensively in the People’s Republic of China. Several Chinese-based studies have demonstrated that the use of acarbose as a monotherapy had similar effects on other anti-diabetes agents in decreasing glycosylated hemoglobin (HbA1c) and blood glucose levels, and acarbose in combination with other anti-diabetic drugs could further reduce blood glucose and decrease the mean amplitude of glycemic excursions. Importantly, acarbose is safe and well tolerated, with a low incidence of adverse effects. This article provides a comprehensive review of the safety and efficacy of acarbose for the treatment of diabetes in Chinese patients. |
| publisher |
Dove Medical Press |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4085335/ |
| _version_ |
1613109439069421568 |